While we have established CRC, HCC and pre-B-ALL as priority cancer targets for α-LGR5-based therapeutics, future studies will determine other targetable cancer types by increased LGR5 protein levels as a prognostic marker. This evidence concerns the gene LGR5 and acute lymphoblastic leukemia.